We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
News

Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression

Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
News

Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.

The proof-of-concept Phase II study with EVT 101, which is being conducted in the United States, has the main objective of studying the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention. Approximately 100 patients suffering from treatment-resistant depression will participate in it. Treatment-resistance of patients will be confirmed in a 6-week prospective antidepressant treatment phase preceding the actual 4-week double-blind treatment.

Treatment-resistance to antidepressant drugs is observed in up to 30% of depressed patients. NMDA receptor antagonists represent an alternative mechanism that has the potential to improve depression in patients resistant to conventional antidepressants.

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, commented: "The clinical development of EVT 101 is addressing an area of significant unmet medical need, and this development represents a big market opportunity. We are happy to have Roche, as a recognized pioneer for novel solutions in the CNS area, for this development with us."
Advertisement